Celebrating 30 Years
This year marks the 30th anniversary of the discovery and establishment of our proprietary NK-92 cell platform. We’re grateful to the dedicated scientists and clinical researchers who have contributed to the development of the first Natural Killer cell-line therapy to enter clinical trials.
Finding Better Treatments for Bladder Cancer
We are pleased to report that the FDA has accepted for review our BLA for N-803 + BCG for BCG-Unresponsive NMIBC CIS. If approved, N-803 plus BCG would be the first immunotherapy combination for this indication in 23 years that can be delivered directly to the bladder to induce natural killer cells and T cells.
We are committed to increasing diversity in clinical trials
Increasing diversity and fostering inclusion among clinical trial participants ensures that trial results help reduce current disparities in healthcare.
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.
Our COVID-19 Research
Our researchers are developing COVID-19 vaccines that are designed to be more practical to make, store, and distribute than existing vaccines, with the potential to protect people from current and future SARS-CoV-2 variants and also be a boost to current COVID-19 vaccines.
Solutions for PatientsMany therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Opportunities for Trial InvestigatorsImmunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.
Solutions for Research ScientistsOur NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious disease in a range of clinical trials at various stages.
Latest News & Events
34th Annual Piper Sandler Healthcare Conference Date: Tuesday, November 29, 2022Location: New York CityWebcast Link:...
CULVER CITY, Calif., November 17, 2022 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company,...
NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer
Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median...